Macrophages and diabetic nephropathy

Seminars in Nephrology

Volumn 30, Issue 3, 2010, Pages 290-301

  Tesch, Greg H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Chemokines; Diabetic nephropathy; Fibrosis; Inflammation; Macrophages

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CELL ADHESION MOLECULE; CELL NUCLEUS RECEPTOR; CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MIZORIBINE; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAPAMYCIN; SPIRONOLACTONE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DISEASE MODEL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INJURY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ANIMALS; CELL ADHESION MOLECULES; CHEMOKINES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; MACROPHAGE ACTIVATION; MACROPHAGES;

EID: 77953877662     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.03.007     Document Type: Article

References (74)

1. Bohle A., Wehrmann M., Bogenschutz O., Batz C., Muller C.A., Muller G.A. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991, 187:251-259.
2. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993, 21:480-485.
3. Nguyen D., Ping F., Mu W., Hill P., Atkins R.C., Chadban S.J. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006, 11:226-231.
4. Yonemoto S., Machiguchi T., Nomura K., Minakata T., Nanno M., Yoshida H. Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus. Clin Exp Nephrol 2006, 10:186-192.
5. Tesch G.H., Allen T.J. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007, 12:261-266.
6. Young B.A., Johnson R.J., Alpers C.E., Eng E., Gordon K., Floege J., et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995, 47:935-944.
7. Sassy-Prigent C., Heudes D., Mandet C., Belair M.F., Michel O., Perdereau B., et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475.
8. Chow F.Y., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004, 19:2987-2996.
9. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
10. Yuan H., Lanting L., Xu Z.G., Li S.L., Swiderski P., Putta S., et al. Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 2008, 295:F605-F617.
11. Lassila M., Seah K.K., Allen T.J., Thallas V., Thomas M.C., Candido R., et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004, 15:2125-2138.
12. Sato W., Kosugi T., Zhang L., Roncal C.A., Heinig M., Campbell-Thompson M., et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest 2008, 88:949-961.
13. Fujita H., Fujishima H., Chida S., Takahashi K., Qi Z., Kanetsuna Y., et al. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 2009, 20:1303-1313.
14. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004, 65:116-128.
15. Ninichuk V., Kulkarni O., Clauss S., Anders H.J. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Eur J Med Res 2007, 12:351-355.
16. Lim A.K., Ma F.Y., Nikolic-Paterson D.J., Thomas M.C., Hurst L.A., Tesch G.H. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009, 52:1669-1679.
17. Mohan S., Reddick R.L., Musi N., Horn D.A., Yan B., Prihoda T.J., et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008, 88:515-528.
18. Phillips A.O., Baboolal K., Riley S., Grone H., Janssen U., Steadman R., et al. Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis 2001, 37:400-410.
19. Kikuchi Y., Imakiire T., Yamada M., Saigusa T., Hyodo T., Hyodo N., et al. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 2005, 20:1573-1581.
20. Dominguez J., Wu P., Packer C.S., Temm C., Kelly K.J. Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy. Am J Physiol Renal Physiol 2007, 293:F670-F679.
21. Coimbra T.M., Janssen U., Grone H.J., Ostendorf T., Kunter U., Schmidt H., et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000, 57:167-182.
22. Hirata K., Shikata K., Matsuda M., Akiyama K., Sugimoto H., Kushiro M., et al. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 1998, 41:185-192.
23. Sugimoto H., Shikata K., Hirata K., Akiyama K., Matsuda M., Kushiro M., et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997, 46:2075-2081.
24. Seron D., Cameron J.S., Haskard D.O. Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dial Transplant 1991, 6:917-922.
25. Altannavch T.S., Roubalova K., Kucera P., Andel M. Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res 2004, 53:77-82.
26. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96:1395-1403.
27. Vlassara H., Fuh H., Donnelly T., Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995, 1:447-456.
28. Park C.W., Kim J.H., Lee J.H., Kim Y.S., Ahn H.J., Shin Y.S., et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000, 43:1544-1553.
29. Kosugi T., Nakayama T., Heinig M., Zhang L., Yuzawa Y., Sanchez-Lozada L.G., et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009, 297:F481-F488.
30. Okada S., Shikata K., Matsuda M., Ogawa D., Usui H., Kido Y., et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593.
31. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Tesch G.H. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005, 16:1711-1722.
32. Yamaguchi H., Igarashi M., Hirata A., Tsuchiya H., Sugiyama K., Morita Y., et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 2004, 51:499-504.
33. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
34. Junaid A., Amara F.M. Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004, 44:136-146.
35. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Rollins B.J., Tesch G.H. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
36. Hsieh T.J., Chen R., Zhang S.L., Liu F., Brezniceanu M.L., Whiteside C.I., et al. Upregulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney Int 2006, 69:1005-1015.
37. Gu L., Hagiwara S., Fan Q., Tanimoto M., Kobata M., Yamashita M., et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006, 21:299-313.
38. Matsui T., Yamagishi S., Ueda S., Nakamura K., Imaizumi T., Takeuchi M., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007, 35:482-489.
39. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
40. Thallas-Bonke V., Thorpe S.R., Coughlan M.T., Fukami K., Yap F.Y., Sourris K.C., et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008, 57:460-469.
41. Lorenzen J., Shah R., Biser A., Staicu S.A., Niranjan T., Garcia A.M., et al. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol 2008, 19:884-890.
42. Usui H.K., Shikata K., Sasaki M., Okada S., Matsuda M., Shikata Y., et al. Macrophage scavenger receptor-A-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007, 56:363-372.
43. Adhikary L., Chow F., Nikolic-Paterson D.J., Stambe C., Dowling J., Atkins R.C., et al. Abnormal p38 mitogen-activated protein kinase signaling in human and experimental diabetic nephropathy. Diabetologia 2004, 47:1210-1222.
44. Hayek T., Kaplan M., Kerry R., Aviram M. Macrophage NADPH oxidase activation, impaired cholesterol fluxes, and increased cholesterol biosynthesis in diabetic mice: a stimulatory role for D-glucose. Atherosclerosis 2007, 195:277-286.
45. Jain S.K., Kannan K., Lim G., McVie R., Bocchini J.A. Hyperketonemia increases tumor necrosis factor-alpha secretion in cultured U937 monocytes and type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency. Diabetes 2002, 51:2287-2293.
46. Guha M., Bai W., Nadler J.L., Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000, 275:17728-17739.
47. He C.J., Koschinsky T., Buenting C., Vlassara H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 2001, 7:159-168.
48. Takahashi H.K., Mori S., Wake H., Liu K., Yoshino T., Ohashi K., et al. Advanced glycation end products subspecies selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 2009, 330:89-98.
49. Wu C.H., Huang C.M., Lin C.H., Ho Y.S., Chen C.M., Lee H.M. Advanced glycosylation end products induce NF-kappaB dependent iNOS expression in RAW 264.7 cells. Mol Cell Endocrinol 2002, 194:9-17.
50. Cohen M.P., Shea E., Chen S., Shearman C.W. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003, 141:242-249.
51. Li J., Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997, 272:16498-16506.
52. Keidar S., Kaplan M., Pavlotzky E., Coleman R., Hayek T., Hamoud S., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
53. Boyle J.J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005, 3:63-68.
54. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273:25573-25580.
55. Crisafulli C., Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages. Shock 2009, 32:62-73.
56. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
57. Berbaum K., Shanmugam K., Stuchbury G., Wiede F., Korner H., Munch G. Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine 2008, 41:198-203.
58. Tesch G.H. Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol 2007, 34:1016-1019.
59. Lim A.K., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Thomas M.C., Flavell R.A., et al. Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 2009, 52:347-358.
60. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
61. Onozato M.L., Tojo A., Goto A., Fujita T. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int 2004, 65:951-960.
62. Lee F.T., Cao Z., Long D.M., Panagiotopoulos S., Jerums G., Cooper M.E., et al. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004, 15:2139-2151.
63. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006, 91:2214-2217.
64. Guo C., Martinez-Vasquez D., Mendez G.P., Toniolo M.F., Yao T.M., Oestreicher E.M., et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006, 147:5363-5373.
65. Loike J.D., Shabtai D.Y., Neuhut R., Malitzky S., Lu E., Husemann J., et al. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol 2004, 24:2051-2056.
66. Wu Y.G., Lin H., Qian H., Zhao M., Qi X.M., Wu G.Z., et al. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 2006, 55:192-199.
67. Wittmann S., Daniel C., Stief A., Vogelbacher R., Amann K., Hugo C. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 2009, 87:1290-1299.
68. Yang Y., Wang J., Qin L., Shou Z., Zhao J., Wang H., et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007, 27:495-502.
69. Kanamori H., Matsubara T., Mima A., Sumi E., Nagai K., Takahashi T., et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007, 360:772-777.
70. Ninichuk V., Clauss S., Kulkarni O., Schmid H., Segerer S., Radomska E., et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008, 172:628-637.
71. Ninichuk V., Khandoga A.G., Segerer S., Loetscher P., Schlapbach A., Revesz L., et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007, 170:1267-1276.
72. Ma F.Y., Liu J., Kitching A.R., Manthey C.L., Nikolic-Paterson D.J. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Am J Physiol Renal Physiol 2009, 296:F177-F185.
73. Tofovic S.P., Salah E.M., Jackson E.K., Melhem M. Early renal injury induced by caffeine consumption in obese, diabetic ZSF1 rats. Ren Fail 2007, 29:891-902.
74. Jung D.S., Li J.J., Kwak S.J., Lee S.H., Park J., Song Y.S., et al. FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high glucose stimulated mesangial cells. Am J Physiol Renal Physiol 2008, 295:F595-F604.